Arginine deiminase
Alternative Names: CX 108; GI-IILatest Information Update: 24 Oct 2021
At a glance
- Originator Nikko Kyodo
- Class Antineoplastics; Hydrolases
- Mechanism of Action Enzyme stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 07 Jun 2001 Discontinued-Preclinical for Cancer in Japan (Unknown route)